David R. Chen

• Counsel to Braveheart Bio on licensing HRS-1893, a myosin inhibitor for the treatment of obstructive hypertrophic cardiomyopathy, from Jiangsu Hengrui and completing its $185M Series A financing
• Counsel to Sidera Bio on licensing MWN105, a GLP-1/FIP/FGF21 triple agonist for the treatment of obesity, from Shanghai Minwei Biotech, which successfully launched with a $109M Series A financing
• Counsel to Engine Biosciences, a Singapore-based biotech, on licensing several therapeutic assets
• Counsel to Leads Bio on its exclusive license of LBL-047, a pre-clinical bispecific antibody for the treatment of autoimmune disorders, to Dianthus Therapeutics for $38M in upfront and near-term milestone payments, with total deal value of up to $1B
• Counsel to Rapport Therapeutics on its exclusive license of Greater China rights to RAP-219 to Tenacia Biotechnology for up to $308M, including a $20M cash upfront
• Counsel to Kelun Biotech and Harbour Biomed on licensing a bispecific antibody T-cell engager asset to Windward Bio, which successfully launched with $200M Series A financing
• Counsel to Ouro Medicines on licensing a bispecific antibody T-cell engager asset from KeyMed Biosciences, and formation of newco company, Platina Medicines, and its $120M Series A financing
• Counsel to Terns Pharmaceuticals (NASDAQ: TERN) on various strategic initiatives and IP licensing matters
• Counsel to EIT Pharma on its acquisition of lonafarnib for the treatment of Hepatitis D Virus and other antiviral indications and PEG-interferon lambda from Eiger Biopharmaceuticals as part of Eiger Biopharmaceutical’s bankruptcy
• Counsel to Innovent Biologics on its licensing of China commercialization rights to Jayprica® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, from Eli Lilly
• Counsel to Genezen on acquiring uniQure (NASDAQ: QURE)’s commercial gene therapy manufacturing operations and facility together with strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX® product, the first one-time gene therapy approved in the US and Europe for the treatment of adults with severe and moderately severe Hemophilia B
• Counsel to CASI Pharmaceuticals (NASDAQ: CASI) on multiple in-license transactions for pharmaceutical assets, including a license transaction for a radiopharmaceutical product, and transactions with several US-based/listed biotechs and an European biotech*
• Lead counsel advising BeiGene (NASDAQ: BGNE; HKG: 6160), a leading China-based, global integrated pharmaceutical company, on an in-license from a HK-listed pharmaceutical company of a late-stage pharmaceutical product for China*
• Lead counsel advising LianBio (NASDAQ: LIAN; HKG: 9688), a leading China-based biotechnology company, on multiple in-licensing initiatives to develop and commercialize products for China, related clinical collaboration, supply, and commercialization arrangements, and alliance management matters*
• Counsel to Innovent Biologics (HKG: 1801) on several licensing and distribution transactions involving Innovent’s products in emerging markets
• Lead counsel advising Zai Lab (NASDAQ: ZLAB), a leading China-based biotechnology company, on multiple in-licensing initiatives and research collaborations to develop and commercialize products for China, including transactions with several US-based/listed biotechs*
• Counsel to Innovent Biologics (HKG: 1801) in its multiple-asset license and collaboration agreement with Eli Lilly & Company, and with respect to multiple related ancillary agreements and amendments*
• Lead counsel advising Innovent Biologics (HKG: 1801), a leading China-based pharmaceutical company, on multiple in-licensing and out-licensing arrangements, including transactions with a leading US cancer center, several US listed biotechs, and a large US multinational pharmaceutical company (MNC)*
• Lead counsel advising Agenus (NASDAQ: AGEN), a US-based biotechnology company, on multiple out-license transactions for various products for China and worldwide, including transactions with a China-listed pharmaceutical company and a large US MNC*
• Lead counsel advising a large US MNC on its in-license from a wholly owned subsidiary of a leading Chinese biotech and life sciences service provider of an adeno-associated viral (AAV) vector technology platform for the development and commercialization of gene therapies*
• Lead counsel advising a large US MNC on its collaboration with a China-based precision medicine company to develop AI algorithms for the early detection and diagnosis of lung cancer*
• Lead counsel advising a large US MNC on its collaboration with a Chengdu-based early-stage CRO for designing and building DNA-encoded libraries to discover unique small molecule assets*
• Counsel to a large US MNC on a license-option arrangement for various antibody pipeline assets of a Chinese biotech*
• Lead counsel advising a large US MNC on a license-option arrangement for a digital health, medical device product*
• Lead counsel advising MediBoston, a US- and China-based anti-body drug conjugate (ADC) biotechnology company, on several ADC development collaborations with a HK-listed pharmaceutical company and various European biotechs*
• Represented Mersana (NASDAQ: MRSN), a leading US ADC biotechnology company, on multiple ADC license transactions, including transactions with a large Japanese MNC*
• Lead licensing counsel advising HutchMed (NASDAQ: HCM; HKG: 0013) on its in-license of cell-lines for the development and commercialization of biologic therapeutics*
• Lead counsel advising BioNova Pharmaceuticals, a China-based foreign-invested biotechnology company, on multiple in-license transactions with several US-based biotechs for pharmaceutical assets, including ADCs*
• Counsel to Abbisko Therapeutics (HKG:2256), a HK-listed, China-based biotechnology company, on its in-license of greater China rights for an oncology asset from a NASDAQ-listed biotech*
• Lead counsel advising Wallaby Medical, a leading US- and China-based neurovascular medical device company, on various medical device and digital health-related in-licensing, out-licensing, and distribution arrangements, including transactions with a German-based medical technology company and a UK-based AI/digital health company*
• Lead counsel advising Mallinckrodt (NYSE: MNK) on its out-license, development, distribution, and supply arrangements with its HK-listed China distributor for a drug/device combination product*
• Counsel to Bellerophon Therapeutics (NASDAQ: BLPH), a US listed, clinical-stage, biotherapeutics company, on its out-license arrangements with its China partner for a drug/device combination product*
• Lead licensing counsel advising Waters Corporation (NYSE: WAT) on its out-license, development, distribution, and supply arrangements with its China distributor for a medical device product*
• Counsel to Simcere (HKG: 2096) in a collaboration and license arrangement with Merus (NASDAQ: MRUS) to in-license bi-specific antibodies*
• Counsel to Harbin Pharmaceuticals (SHA: 600664) in its partnership and license with GNC for the sale of GNC-branded products in China*

*Denotes experience prior to joining Goodwin.

• Lead counsel advising a large US MNC to engage a large European MNC in two separate transactions to promote its diabetes product in China and Southeast Asia*
• Lead counsel advising a large US MNC on several authorized generic supply and distribution arrangements for various products in Japan, including transactions with a large Japanese pharmaceutical company*
• Lead counsel advising a large US MNC on several reverse co-promotion arrangements for various products in Japan, including transactions with a large Japanese pharmaceutical company*
• Counsel to a large US MNC on an exclusive distribution and promotion arrangement for a product in Japan*
• Lead counsel advising Amgen (NASDAQ: AMGN) on several co-promotion arrangements in China*
• Co-licensing/commercial counsel advising Zai Lab on a promotion arrangement for China with a leading China-based pharmaceutical company*

*Denotes experience prior to joining Goodwin.

• Counsel to Engine Biosciences, a Singapore-based biotech, on acquiring a therapeutic target and related assets
• Counsel to BioNova Pharmaceuticals on its sale to Servier Pharmaceuticals of BN104, a potential best-in-class phase 1/2 menin inhibitor for the treatment of leukemia
• Counsel to Ouro Medicines on its sale to Gilead Sciences for $1.7B cash up front, and $500M in contingent milestone payments

• Counsel to Alibaba (NYSE: BABA) on its strategic partnership with Richemont to bring the retail offerings of YOOX Net-A-Porter Group, a leading online luxury fashion retailer, to Chinese consumers*
• Counsel to Alibaba on its investment in Unity China, a joint venture of Unity Technologies (NYSE: U) for the development and commercialization of localized versions of Unity game development products, including Unity’s core product, Unity Editor.*
• Counsel to Alibaba on business cooperation agreements and IP and data-related matters in connection with various strategic investments*
• Counsel to Ant Financial on business cooperation agreements and IP and data-related matters in connection with various strategic investments*
• Counsel to NetEase (NASDAQ: NTES) on various strategic investments and in-license arrangements in the gaming sector, including to bring the popular games Minecraft and Pokemon Go to the Chinese market*
• Lead counsel advising Seer (NASDAQ: SEER), a US-based proteomics data analysis company, on its SaaS service arrangements in China*
• Lead counsel advising Veracross, a US-based student information systems and software company, on its SaaS service arrangements in China*
• Lead counsel advising Luca Healthcare, a China-based digital health company, on various digital health in-licensing initiatives, including a transaction with a US-based neuroscience digital health company*
• Lead counsel advising Healthwise, a US-based health education and information company, on its content license arrangement with Tencent to distribute Healthwise content in China*

*Denotes experience prior to joining Goodwin.

• Advised Templewater on its acquisition of The Women’s Clinic Group
• Lead counsel advising BioNova Pharmaceuticals, a China-based foreign-invested biotechnology company, on the sale to Servier of BN104, a potential best-in-class menin inhibitor currently in Phase 1/2 development for the treatment of acute leukemias
• Advised various investment funds on intellectual property matters in connection with investments several leading artificial intelligence (AI) companies
• Advised Templewater on its acquisition of the Hong Kong operations and assets of Icon Group, an Australian-based cancer care provider
• Counsel to a large US MNC on its reverse co-promotion arrangement for its product in Japan
• Lead counsel advising BioNova Pharmaceuticals, a China-based foreign-invested biotechnology company, on the sale of its approved product REZUROCK® (belumosudil) in China to Sanofi (NASDAQ: SNY)
• Counsel to a large US MNC on its divestment of a product in Japan*
• Counsel to a large US MNC on its divestment of its rest-of-the-world rights to a product*
• Licensing/commercial transactions counsel advising Eli Lilly and Company (NYSE: LLY) on multiple divestitures involving several products in China*
• Advised Alibaba on investments in companies operating in a broad range of sectors, including e-commerce, artificial intelligence (AI), autonomous driving, electric vehicles (EVs), social media, online travel, and logistics*
• Advised Ant Financial on investments in companies in various sectors, including fintech, technology services, and online reviews*
• Advised DST Global, a leading venture capital and private equity firm, on IP and data-related matters in connection with its investments in various sectors, including consumer products, wellness, apparel, and food & beverage*
• Advised a consortium of investors, including TPG Capital, in a going-private transaction involving Shangpharma, one of the largest Chinese life sciences service providers*
• Advised MBK Partners on its investment in a leading Chinese medical data and oncology big data company*
• Advised a US children’s clothing company in the negotiation of a joint venture to launch and operate its branded children’s apparel business in China*
• Advised a Caterpillar (NYSE: CAT) on several joint ventures to operate industrial equipment manufacturing business in China*
• Advised LINE Corporation/Naver in the negotiation of several joint ventures to operate online businesses in China*
• Regularly advise private equity and other investment funds, including Baring, Blackstone, Bain, TPG, Goldman Sachs, KPCB, DST, MBK Partners, Pivotal BioVentures, Panacea, CMC Capital, and Milestone, on IP and data-related due diligence and contract provisions in transaction documents in connection with investment transactions in a variety of sectors, including social media, e-commerce, digital technology products, consumer brands, network equipment manufacturers, telecommunications, and life sciences*

*Denotes experience prior to joining Goodwin.

• Advised Toast, Inc. on various cybersecurity matters
• Advised a leading sports betting company in Hong Kong on various cybersecurity matters
• Regularly advise life sciences companies and private equity and other investment funds on China and Hong Kong data protection compliance matters, including compliance counseling, privacy notices and consents, privacy programs, data transfer agreements, privacy risk assessments, and compliance with China and Hong Kong cross-border data transfer requirements*
• Advised Zai Lab on a data transfer agreement with a US-based, multi-national licensor partner for the cross-border sharing of clinical data*
• Advised a US-listed e-commerce company on a data privacy risk assessment covering its primary operating markets in multiple countries across Asia-Pacific*
• Advised a Hong Kong-based private equity fund in connection with a data breach/ransomware attack*

*Denotes experience prior to joining Goodwin.